Role of the surgical pathologist for tissue management in oncology;Rôle du pathologiste dans la prise en charge des tissus en oncologie

Bulletin du Cancer

Volumn 100, Issue 9, 2013, Pages 837-845

  Long, Elodie ^a   Ilie, Marius ^a   Hofman, Véronique ^a   Lassalle, Sandra ^a   Butori, Catherine ^a   Alsubaie, Saad ^a   Hofman, Paul ^a  

^a PASTEUR HOSPITAL   (France)

Author keywords

Biomarker; Biopsy; Fixative; Frozen procedure; Immunohistochemistry; In situ hybridization; Molecular biology

Indexed keywords

ARTICLE; DNA EXTRACTION; GENETIC ANALYSIS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFLAMMATORY CELL; MOLECULAR BIOLOGY; PATHOLOGIST; PROGNOSIS; TUMOR CELL;

EID: 84884779784     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2013.1803     Document Type: Article

References (30)

1. Long E, Hofman V, Ilie M, et al. Accréditation de l'activité de pathologie moléculaire selon la norme ISO 15189. Principales étapes à respecter et principaux écueils possibles. Ann Pathol 2013; 33: 12-23.
2. Long E, Hofman V, Ilie M, et al. Mise en place d'un secteur de pathologie moléculaire en oncologie au sein d'un laboratoire d'anatomie pathologique (LPCE, CHU de Nice). Ann Pathol 2013; 33: 24-37.
3. Hofman V, Ilie M, Gavric-Tanga V, et al. Rôle du laboratoire d'anatomie-pathologique dans l'approche pré-analytique des examens de biologie moléculaire réalisés en pathologie tumorale. Ann Pathol 2010; 30: 85-93.
4. Lassalle L, Hofman V, Ilie M, et al. Setting up a prospective thyroid biobank for translational research: practical approach of a single institution (2004-2009, Pasteur Hospital, Nice, France). Biopreservation Biobanking 2011; 2: 1-11.
5. Bussolati G, Chiusa L, Cimino A, D'Armento G. Tissue transfer to pathology labs: under vacuum is the safe alternative to formalin. Virchows Arch 2008; 452: 229-31.
6. http://www.rfidjournal.com/article/view/8303/French Biobank Secures Specimens
7. Housseman S, Absi N, Dauzère-Pérès S, Daufresne LM, Hofman P. Les NTIC dans la gestion d'un stock d'échantillons biologiques. La simulation pour aider à la décision. Gest Hosp 2012; 513: 91-5.
8. Hofman P. Quels fixateurs ? Pour quelles indications ? Principaux critères d'évaluation des méthodes alternatives à la fixation du formol. Rev Fr Lab 2009; 408: 1-4.
9. Stanta G, Mucelli SP, Petrera F, Bonin S, Bussolati G. A novel fixative improves opportunities of nucleic acids and proteomic analysis in human archive's tissues. Diagn Mol Pathol 2006; 15: 115-23.
10. http://www.legifrance.gouv.fr/ArticleR231-56-3. Abrogé par décret no 2008-244 du 7 mars 2008-art.9 (V).
11. Hofman V, Selva E, Chabannon C, et al. Les biobanques en France: enjeux et contraintes. Rev Fr Lab 2010; 418: 67-72.
12. Hewitt SM, Lewis FA, Cao Y, et al. Tissue handling and specimen preparation in surgical pathology: issues concerning the recovery of nucleic acids from formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med 2008; 132: 1929-35.
13. Koshiba M, Ogawa K, Hamazaki S, Sugiyama T, Ogawa O, Kitajima T. The effect of formalin fixation on DNA and the extraction of high-molecular- weightDNA from fixed and embedded tissues. Pathol Res Pract 1993; 189: 66-72.
14. Lassalle S, Hofman V, Marius I, et al. Assessment of morphology, antigenicity, and nucleic acid integrity for diagnostic thyroid pathology using formalin substitute fixatives. Thyroid 2009; 19: 1239-48.
15. Plénat F. La fixation et les fixateurs: les fondamentaux. Les critères de choix d'un substitut du formol. Ann Pathol 2007; 27: 1S88-1S89.
16. Burford-Mason AP, MacKay AJ, Cummins M, Dardick I. Detection of proliferating cell nuclear antigen in paraffin-embedded specimens is dependent on preembedding tissue handling and fixation. Arch Pathol Lab Med 1994; 118: 1007-13.
17. De Marzo AM, Fedor HH, Gage WR, Rubin MA. Inadequate formalin fixation decreases reliability of p27 immunohistochemical staining: probing optimal fixation time using high-density tissue microarrays. Hum Pathol 2002; 33: 756-60.
18. Goldstein NS, Ferkowicz M, Odish E, Mani A, Hastah F. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol 2003; 120: 86-92.
19. Werner M, Chott A, Fabiano A, Battifora H. Effect of formalin tissue fixation and processing on immunohistochemistry. Am J Surg Pathol 2000; 24: 1016-9.
20. Willmore-Payne C, Metzger K, Layfield LJ. Effects of fixative and fixation protocols on assessment of Her-2/neu oncogene amplification status by fluorescence in situ hybridization. Appl Immunohistochem Mol Morphol 2007; 15: 84-7.
21. Babic A, Loftin IR, Stanislaw S, et al. The impact of pre-analytical processing on staining quality for H&E, dual hapten, dual color in situ hybridization and fluorescent in situ hybridization assays. Methods 2010; 52: 287-300.
22. Hofman P, Ilie M, Hofman V, et al. Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma. Ann Oncol 2012; 23: 1738-43.
23. Ilie MI, Hofman V, Bonnetaud C, et al. Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma. Virchows Arch 2010; 457: 483-95.
24. Kitamura A, Hosoda W, Sasaki E, Mitsudomi T, Yatabe Y. Immunohistochemical detection of EGFR mutation using mutationspecific antibodies in lung cancer. Clin Cancer Res 2010; 16: 3349-55.
25. Mino-Kenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 2010; 16: 1561-71.
26. Ilie M, Hofman P. The potential value of immunohistochemistry as a screening tool for oncogenic targets of personalized lung cancer therapy. J Oncopathol 2013; 1: 82-92.
27. Ilie M, Hofman P. Pitfalls in lung cancer molecular pathology: how to limit them in routine practice? Curr Med Chem 2012; 19: 2638-51.
28. Lassalle S, Hofman V, Ilie M, et al. Can the microRNA signature distinguish between thyroid tumors of uncertain malignant potential and other well-differentiated tumors of the thyroid gland? Endocr Relat Cancer 2011; 18: 579-94.
29. Ortholan C, Puissegur MP, Ilie M, Barbry P, Mari B, Hofman P. MicroRNAs and lung cancer: new oncogenes and tumor suppressors, new prognostic factors and potential therapeutic targets. Curr Med Chem 2009; 16: 1047-61.
30. Scott MG, Smith BR, Wu AH, Young IS, Plebani M, Chiu RW. How well are we training the next generation of clinical pathologists and clinical laboratory directors? A global perspective. Clin Chem 2012; 58: 491-5.